Variant position: 377 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 427 The length of the canonical sequence.
Location on the sequence:
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human PWTKRLVMVKVVPTCLRALV EMARVGGASSLEN-TVDLHISN
Mouse PWVKRLVMVKVVPTCLKELL EMAREGGASSLK--TVDLHIS
Pig PWVKRLVMVKVVPMCLRALV DMARDGGASSLEN-TVDLHIS
Bovine PWIKRLVMVKVVPMCLRVLV DIARQGGASSLEN-TVDLHIS
Chicken PKESKLILVKLVPQFCEYWY EQVQRGGASSLNSGNVSLQLS
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
1 – 427 Interferon regulatory factor 3
141 – 427 Mediates interaction with ZDHHC11
385 – 385 Phosphoserine
386 – 386 Phosphoserine; by TBK1
396 – 396 Phosphoserine; by IKKE and TBK1
360 – 360 Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ISG15)
366 – 366 Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ISG15)
105 – 427 Missing. In isoform 5.
328 – 427 DLITFTEGSGRSPRYALWFCVGESWPQDQPWTKRLVMVKVVPTCLRALVEMARVGGASSLENTVDLHISNSHPLSLTSDQYKAYLQDLVEGMDFQGPGES -> GSWAPRSDYLHGRKRTLTTLCPLVLCGGVMAPGPAVDQEARDGQGCAHVPQGLGRNGPGRGCLLPGEYCGPAHFQQPPTLPHLRPVQGLPAGLGGGHGFPGPWGELSPRSSWCASNPPVPHHLNQ. In isoform 4.
360 – 360 K -> R. Highly diminished ISGylation; when associated with R-193 and R-366.
366 – 366 K -> R. Highly diminished ISGylation; when associated with R-193 and R-360.
385 – 385 S -> ADE. Complete loss of viral infection induced phosphorylation.
386 – 386 S -> ADE. Complete loss of viral infection induced phosphorylation.
386 – 386 S -> E. Phosphomimetic mutant; interacts with CREBBP; when associated with E-396.
396 – 396 S -> E. Phosphomimetic mutant; interacts with CREBBP; when associated with E-386.
370 – 383
No reference for the current variant in UniProtKB/Swiss-Prot.
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.